Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1382

Related Citations for PubMed (Select 16787254)

1.
2.

Modulation of HERG potassium channel function by drug action.

Thomas D, Karle CA, Kiehn J.

Ann Med. 2004;36 Suppl 1:41-6.

PMID:
15176423
3.

[HERG K+ channel, the target of anti-arrhythmias drugs].

Guan FY, Yang SJ.

Yao Xue Xue Bao. 2007 Jul;42(7):687-91. Review. Chinese.

PMID:
17882949
4.

Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.

Witchel HJ, Hancox JC.

Clin Exp Pharmacol Physiol. 2000 Oct;27(10):753-66. Review.

PMID:
11022966
5.

In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.

Inanobe A, Kamiya N, Murakami S, Fukunishi Y, Nakamura H, Kurachi Y.

J Physiol Sci. 2008 Dec;58(7):459-70. doi: 10.2170/physiolsci.RV-0114-08-07-R1. Epub 2008 Nov 27.

PMID:
19032804
6.

The hERG potassium channel as a therapeutic target.

Witchel HJ.

Expert Opin Ther Targets. 2007 Mar;11(3):321-36. Review.

PMID:
17298291
7.

Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.

Wang L, Wible BA, Wan X, Ficker E.

J Pharmacol Exp Ther. 2007 Feb;320(2):525-34. Epub 2006 Nov 9.

8.

hERG potassium channels and cardiac arrhythmia.

Sanguinetti MC, Tristani-Firouzi M.

Nature. 2006 Mar 23;440(7083):463-9. Review.

PMID:
16554806
9.

High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.

Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J.

J Pharmacol Exp Ther. 2001 May;297(2):753-61.

10.

Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.

Perrin MJ, Subbiah RN, Vandenberg JI, Hill AP.

Prog Biophys Mol Biol. 2008 Oct-Nov;98(2-3):137-48. doi: 10.1016/j.pbiomolbio.2008.10.006. Epub 2008 Nov 5. Review.

PMID:
19027781
11.

Molecular determinants of high-affinity drug binding to HERG channels.

Mitcheson JS, Perry MD.

Curr Opin Drug Discov Devel. 2003 Sep;6(5):667-74. Review.

PMID:
14579516
12.

hERG: protein trafficking and potential for therapy and drug side effects.

Staudacher I, Schweizer PA, Katus HA, Thomas D.

Curr Opin Drug Discov Devel. 2010 Jan;13(1):23-30. Review.

PMID:
20047143
14.

QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.

Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F.

Med Res Rev. 2005 Mar;25(2):133-66. Review.

PMID:
15389727
15.

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.

Cardiovasc Res. 2003 Apr 1;58(1):32-45. Review.

16.

hERG channel trafficking: novel targets in drug-induced long QT syndrome.

Dennis A, Wang L, Wan X, Ficker E.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1060-3. Review.

PMID:
17956279
17.

C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon.

Choe CU, Schulze-Bahr E, Neu A, Xu J, Zhu ZI, Sauter K, Bähring R, Priori S, Guicheney P, Mönnig G, Neapolitano C, Heidemann J, Clancy CE, Pongs O, Isbrandt D.

Hum Mol Genet. 2006 Oct 1;15(19):2888-902. Epub 2006 Aug 21.

18.
19.
20.

Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.

Guo J, Gang H, Zhang S.

J Pharmacol Exp Ther. 2006 May;317(2):865-74. Epub 2006 Jan 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk